• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Balkan journal of medical genetics: BJMG >The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma
【24h】

The effects of O6-methyl guanine DNA-methyl transferase promotor methylation and CpG1, CpG2, CpG3 and CpG4 methylation on treatment response and their prognostic significance in patients with glioblastoma

机译：O6-甲基鸟嘌呤DNA-甲基转移酶促进剂甲基化和CpG1，CpG2，CpG3和CpG4甲基化对胶质母细胞瘤患者治疗反应及其预后意义的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This retrospective study examined the prognostic significance and treatment effect of promoter methylation of O6- methyl guanine methyl transferase (MGMT) and meth-ylation of CpG 1, CpG2, CpG3 and CpG4 in glioblastoma (GB) patients received postoperative radiotherapy (PORT), with or without adjuvant temozolomide (TMZ). One hundred patients with GB who received PORT with concomitant TMZ plus adjuvant TMZ or PORT alone, were included. The MGMT promoter methylation of CpG1, CpG2, CpG3 and CpG4 islands were examined. Overall, MGMT-methylation emerged as a significant prognostic factor for better overall survival (OS) and progression-free survival (PFS) [odds ratio (OR): 0.609, 95% confidence interval (95% CI): 0.395-0.939, p = 0.02; OR: 0.662,95% CI: 0.430-1019, p = 0.5, respectively]. The methylation of each CpG1, CpG2, CpG3 and CpG4 islands was found to have no significant effects on OS and the methylation of each CpGl, CpG2 and CpG4 islands had no significant effect on PFS (p 0.05 for all). On the other hand, the methylation of CpG3 had a positive prognostic effect on PFS (OR: 2.1, 95% CI: 0.99-4.67, p = 0.04). In the group that only received radiotherapy (RT), CpG1 and CpC3 methylations were found to have a positive prognostic significance in terms of PFS (OR: 266, 95% CI: 1.05-6.75, p -0.03 for CpG1; OR: 2.4, 95% CI: 1.01-5.92, p = 0.04 for CpG3). The MGMT promoter methylation represents an important biomarker for predicting response to therapy. Individual islands, particularly CpG3, deserves further investigation as a prognostic marker. Further studies need to be done with larger sample sizes to clarify the results.
机译：该回顾性研究检测了术后放疗术后放疗（港口）的胶质母细胞瘤（GB）患者的O6-甲基鸟嘌呤甲基转移酶（MGMT）和甲基甲基甲基转移酶（MGMT）和甲基甲基化合物的预后显着性和治疗效果或没有佐剂毒物（TMZ）。包括一百个GB的GB患者，其中收到了伴随着TMZ加上佐剂TMZ或港口的港口。研究了CpG1，CpG2，CPG3和CPG4岛的MGMT启动子甲基化。总体而言，MgMT-甲基化作为更好的整体存活（OS）和无进展存活（PFS）[差距（或）：0.609,95％置信区间（95％CI）：0.395-0.939，P. = 0.02;或者：0.662,95％CI：0.430-1019，p = 0.5]。发现每个CPG1，CPG2，CPG3和CPG4岛的甲基化对OS没有显着影响，每种CPG1，CPG2和CPG4岛的甲基化对PFS没有显着影响（P <0.05）。另一方面，CpG3的甲基化对PFS具有阳性预后作用（或：2.1,95％CI：0.99-4.67，P = 0.04）。在仅接受放射疗法（RT）的组中，发现CPG1和CPC3甲基化在PFS方面具有阳性预后意义（或：266,95％CI：1.05-6.75，P-0.03用于CPG1;或者：2.4， 95％CI：1.01-5.92，P = 0.04用于CPG3）。 MgMT启动子甲基化代表了一种重要的生物标志物，用于预测对治疗的反应。个别岛屿，特别是CpG3，值得进一步调查作为预后标志物。需要使用更大的样本尺寸来完成进一步的研究，以阐明结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号